HTG Molecular Diagnostics Announces Pricing of Initial Public Offering

TUCSON, Ariz., May 6, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc., a provider of instruments and reagents for molecular profiling applications, today announced the pricing of its initial public offering of 3,570,000 shares of its common stock at an initial public offering price of $14.00 per share. All of the shares of common stock are being offered by HTG. The Company's common stock is expected to begin trading today, May 6, 2015, on the NASDAQ Global Market and under the ticker symbol "HTGM." In addition, HTG has granted the underwriters a 30-day option to purchase up to an additional 535,500 shares of common stock at the offering price. The offering is expected to close on May 11, 2015, subject to customary closing conditions.

Leerink Partners LLC is acting as sole book-running manager for the offering and Canaccord Genuity Inc. and JMP Securities LLC are acting as co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 5, 2015.

This offering will be made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by phone at (800) 808-7525, ext. 6142, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About HTG:

Headquartered in Tucson, Arizona, HTG Molecular Diagnostics' mission is to empower precision medicine at the local level. In 2013, the Company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing.

CONTACT: Westwicke Partners
         Jamar Ismail
         Phone: 415-513-1282
         Email: [email protected]

         TJ Johnson
         President / CEO
         HTG Molecular Diagnostics
         Phone: 520-547-2827 x130
         Email: [email protected]

You May Also Be Interested In

• VICI Properties closes $1.75B senior unsecured notes offering
• Realty Income closes $1B convertible notes offering
• Optimum Communications gets NYSE non-compliance notice over stock price